Edition:
United Kingdom

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

5.41USD
13 Sep 2019
Change (% chg)

-- (--)
Prev Close
$5.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
766,380
52-wk High
$34.63
52-wk Low
$4.98

Latest Key Developments (Source: Significant Developments)

Clovis Oncology Announces Pricing Of $250 Mln Of Convertible Senior Notes
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES PRICING OF $250 MILLION OF CONVERTIBLE SENIOR NOTES.CLOVIS ONCOLOGY INC - PRICING OF $250 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 4.50% CONVERTIBLE SENIOR NOTES DUE 2024.  Full Article

Clovis Oncology Reports Q2 Loss Per Share $2.27
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES SECOND QUARTER 2019 OPERATING RESULTS.Q2 LOSS PER SHARE $2.27.Q2 EARNINGS PER SHARE ESTIMATE $-1.71 -- REFINITIV IBES DATA.$33.0M IN RUBRACA(®) (RUCAPARIB) NET PRODUCT REVENUE FOR Q2 2019 COMPARED TO $23.8M FOR Q2 2018.GLOBAL NET PRODUCT REVENUE GUIDANCE OF $137 MILLION TO $147 MILLION PROVIDED FOR FULL YEAR 2019.SUPPLEMENTAL NDA FOR RUBRACA IN BRCA-MUTANT ADVANCED PROSTATE CANCER ON TRACK FOR Q4 2019.CLOVIS HAD $315.9 MILLION IN CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES AS OF JUNE 30, 2019.  Full Article

Clovis Oncology Names Ginger Graham As Board Chair
Thursday, 6 Jun 2019 

June 6 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY NAMES GINGER L. GRAHAM AS NEW BOARD OF DIRECTORS CHAIR.CLOVIS ONCOLOGY INC - M. JAMES BARRETT, CHAIR SINCE INCEPTION, RETIRES FROM BOARD OF DIRECTORS.CLOVIS ONCOLOGY INC - M. JAMES BARRETT RETIRES FROM BOARD OF DIRECTORS.  Full Article

Clovis Oncology Says Expanded Rubraca Data From Ariel3 And Triton2 Trials In Ovarian And Prostate Cancers To Be Presented At 2019 ASCO Annual Meeting
Saturday, 1 Jun 2019 

June 1 (Reuters) - Clovis Oncology Inc ::EXPANDED RUBRACA® (RUCAPARIB) DATA FROM CLOVIS ONCOLOGY’S ARIEL3 AND TRITON2 TRIALS IN OVARIAN AND PROSTATE CANCERS TO BE PRESENTED AT 2019 ASCO ANNUAL MEETING.CLOVIS ONCOLOGY INC - UPDATED SAFETY PROFILE GENERATED IN ANALYSIS IS CONSISTENT WITH PREVIOUSLY-REPORTED PRIMARY EFFICACY DATA ANALYSIS.CLOVIS ONCOLOGY - DATA POSITIVELY REINFORCE CURRENT CLINICAL UTILIZATION & UNDERSTANDING OF RUCAPARIB AS MAINTENANCE TREATMENT FOR WOMEN WITH ADVANCED OVARIAN CANCER.  Full Article

Clovis Oncology Reports Q1 Loss Per Share $1.63
Tuesday, 7 May 2019 

May 7 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2019 OPERATING RESULTS.Q1 LOSS PER SHARE $1.63.Q1 EARNINGS PER SHARE ESTIMATE $-1.74 -- REFINITIV IBES DATA.33.1M IN RUBRACA (RUCAPARIB) GLOBAL SALES FOR Q1 OF 2018.TARGETING LATE 2019 FOR SUPPLEMENTAL NDA FILING FOR BRCA-MUTANT ADVANCED PROSTATE CANCER.$406.8M IN CASH, CASH EQUIVALENTS AND AVAILABLE FOR SALE SECURITIES AT MARCH 31, 2019.CLOVIS-SPONSORED COMBINATION STUDIES OF LUCITANIB WITH RUCAPARIB AND BRISTOL-MYERS SQUIBB'S OPDIVO EXPECTED TO BEGIN IN MID-2019.Q1 REVENUE VIEW $32.2 MILLION -- REFINITIV IBES DATA.  Full Article

Clovis Oncology Says Discontinuing Phase 2 Monotherapy Clinical Trial Evaluating Rucaparib In Bladder Cancer
Friday, 12 Apr 2019 

April 12 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY - DISCONTINUING SPONSORED PHASE 2 OPEN-LABEL MONOTHERAPY CLINICAL TRIAL EVALUATING RUCAPARIB IN RECURRENT, METASTATIC BLADDER CANCER.CLOVIS - DISCONTINUATION DECISION BASED ON RECOMMENDATIONS BY INDEPENDENT DMC AFTER REVIEW OF PRELIMINARY EFFICACY DATA FOR 62 PATIENTS IN STUDY.CLOVIS- PRELIM DATA IN STUDY DEMONSTRATED OBJECTIVE RESPONSE RATE IN INTENT-TO-TREAT POPULATION DOES NOT MEET PROTOCOL-DEFINED CONTINUANCE CRITERIA.CLOVIS - PRELIMINARY DATA IN STUDY SUGGESTS TREATMENT WITH MONOTHERAPY RUCAPARIB MAY NOT PROVIDE MEANINGFUL CLINICAL BENEFIT TO PATIENTS.CLOVIS ONCOLOGY INC - DMC RECOMMENDED TO STOP ENROLLMENT TO STUDY, AND CLOVIS HAS DECIDED TO TERMINATE ATLAS TRIAL EARLY.CLOVIS ONCOLOGY INC - RECOMMENDATION OF DMC WAS NOT BASED ON SAFETY PROFILE OF RUCAPARIB IN THIS STUDY POPULATION.CLOVIS ONCOLOGY INC - CONTINUING TO EVALUATE POTENTIAL FOR RUCAPARIB IN COMBINATION WITH OTHER AGENTS FOR TREATMENT OF ADVANCED BLADDER CANCER.CLOVIS - TO ENROLL PATIENTS WITH ADVANCED BLADDER CANCER & SELECTED GENETIC MUTATIONS IN PLANNED PAN-TUMOR TRIAL OF RUCAPARIB EXPECTED TO START H2 2019.  Full Article

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Clovis Oncology Inc ::ALKERMES AND CLOVIS ONCOLOGY INITIATE RESEARCH COLLABORATION TO EXPLORE COMBINATION CANCER THERAPIES.CLOVIS ONCOLOGY- ALKERMES, CO TO EXAMINE COMBINATIONS OF ALKS 4230 WITH RUCAPARIB & ALKS 4230 WITH LUCITANIB IN MULTIPLE MODELS IN PRECLINICAL STUDIES.CLOVIS ONCOLOGY INC - COMPANIES WILL SHARE COSTS RELATED TO PRECLINICAL STUDIES.  Full Article

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Alkermes Plc ::ALKERMES AND CLOVIS ONCOLOGY INITIATE RESEARCH COLLABORATION TO EXPLORE COMBINATION CANCER THERAPIES.CLOVIS ONCOLOGY INC - COMBINATIONS OF ALKS 4230 WITH RUCAPARIB AND LUCITANIB TO BE EVALUATED IN MULTIPLE PRECLINICAL TUMOR MODELS.CLOVIS - COMPANIES WILL SHARE COSTS RELATED TO PRECLINICAL STUDIES, AND EACH WILL CONTRIBUTE THEIR RESPECTIVE COMPOUNDS TO RESEARCH COLLABORATION..  Full Article

Armistice Capital Reports 9.8 Pct Stake In Clovis Oncology As Of Oct 24
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Clovis Oncology Inc ::ARMISTICE CAPITAL, LLC REPORTS 9.8 PERCENT STAKE IN CLOVIS ONCOLOGY INC AS OF OCTOBER 24 - SEC FILING.ARMISTICE CAPITAL SAYS PURCHASED SHARES ON BELIEF CLOVIS ONCOLOGY'S SHARES, WHEN PURCHASED, WERE UNDERVALUED.  Full Article

Clovis Oncology Reports Q3 Loss Per Share Of $1.71
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2018 OPERATING RESULTS.Q3 LOSS PER SHARE $1.71.Q3 EARNINGS PER SHARE VIEW $-1.60 -- THOMSON REUTERS I/B/E/S.COMPANY ANTICIPATES Q4 2018 REVENUES TO BE CONSISTENT WITH OR SLIGHTLY HIGHER THAN Q3 2018.ANTICIPATES PROVIDING FULL-YEAR 2019 GUIDANCE IN EARLY JANUARY..  Full Article